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acute side effect (16 pts). There was 1 episode of G3 dyspnea possibly 
treatment related, but no other >G2 events. One pt developed G2 RT 
pneumonitis. 9 pts developed late chest pain at 3-21 mo post SBRT; 
4 of those developed rib fractures in the RT ﬁeld area, 11-21 mo post 
SBRT. In 38 evaluable pts (40 tumors), 6 CR and 24 PR were observed. 
There were no local failures in 36 pts with peripheral tumors, but 2 fail-
ures in pts treated with the lower 50 Gy/10 fr schedule. CBCT tumor 
matching compared to bone matching resulted in a mean difference of 
6.8mm (±4.9), the difference was >13.9 mm in 10% of pts; this would 
have resulted in very signiﬁcant tumor miss if portal imaging was used 
without proper visualization of the target. 
Conclusion: These results conﬁrm that lung SBRT gives high rates 
(95%) of local control with the only local failures observed in the 
centrally-located tumors treated with lower dose of 50 Gy/10 fr. Acute 
toxicity is low; rib fracture is the most common late toxicity. CBCT 
greatly improves the accurate delivery of high radioablative doses of 
SBRT for early stage lung cancer.
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Background: The standard radiation dose for NSCLC was established 
by RTOG 7301 as 60 Gy. Local failure rates with this dose remain 
unacceptably high. In preparation for a anticipated Phase III compari-
son of high dose versus standard dose radiation therapy, this Phase I/II 
study was initiated to establish the maximum tolerated dose (MTD) 
of radiation therapy, in the setting of concurrent chemotherapy, using 
3DCRT for NSCLC. 
Methods: Eligibility included patients with histologically proven, unre-
sectable Stages I-III NSCLC and a Zubrod perfomance status of 0-1. 
Weight loss eligibility was <10%. Concurrent chemotherapy consisted 
of paclitaxel 50 mg/m2 and carboplatin AUC=2 given weekly. Radia-
tion (RT) dose was started at 75.25 Gy/35 fractions. Once the MTD 
was reached, the phase II portion of the study was initiated and contin-
ues to accrue. Radiation therapy volumes consisted of gross tumor and 
nodes plus a margin. Elective lymph nodes were not included in the 
treatment ﬁelds. Technical criteria included strict dosimetric constraints 
on the normal lung (V20 <30%) and esophagus (mean dose <34 Gy 
and V55 < 30%) and water-based dose calculations prescribed to the 
isocenter.
Results: The Phase I portion of this study accrued 17 patients from 8 
institutions and was closed in January 2004. After the initial 8 patients 
were accrued to Arm 1, the trial closed temporarily on September 
26, 2002 due to reported toxicity. Two acute treatment-related DLTs 
were reported: a grade 5 infection/febrile neutropenia and a grade 3 
pneumonitis. The protocol, therefore, was revised to de-escalate the 
RT dose (74 Gy/37 fractions). Arm 2 accrued 9 patients with 2 (22%) 
developing Grade 3 GI toxicities and 1 (11%) reporting a Grade 3 in-
fection/febrile neutropenia. Phase II has accrued 31 eligible patients at 
74 Gy. Of the 27 (87%) patients with acute toxicity information, there 
were 3 (11%) Grade 3 pain toxicities, 2 (7%) Grade 3 infection/febrile 
neutropenia toxicities, 1 (4%) Grade 3 pulmonary toxicity, and 1 (4%) 
Grade 3 skin toxicity. A total of 13 (48%) patients reported grade 3+ 
non-hematologic toxicities.
Conclusions: The MTD was determined to be 74 Gy/37 fractions (2.0 
Gy per fraction) using 3DCRT with concurrent paclitaxel and carbo-
platin. Four (11%) grade 3 pulmonary or infection/febrile neutropenia 
toxicities have occurred at the 74 Gy dose level. The Phase II compo-
nent of RTOG L-0117 will close with the opening of our Phase III trial 
(RTOG 0617).
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Introduction: The standard therapy for non-small cell lung cancer 
(NSCLC) brain metastases involves radiotherapy and/or surgical 
resection for all visible lesions. This practice has been based on the 
assumption that brain metastases are less sensitive to systemic therapies 
and has been shown to palliate brain metastasis-related symptoms and 
to improve survival. Similarly, we hypothesize that additional local 
therapy for other sites of disease, particularly the primary tumor and 
locoregional lymph node metastases, may further improve survival. 
Methods: Patients with metastatic NSCLC who received ablative 
local therapy of primary disease - radiotherapy (≥ 45 Gy) or surgical 
resection of their primary tumor and locoregional lymph nodes - tend to 
have a low volume of disease prior to treatment. To identify those who 
received this deﬁnitive local therapy, we searched the M.D. Anderson 
Cancer Center Tumor Registry, Thoracic Radiation Oncology, and Neu-
rosurgery databases, for patients with only one organ site of metastasis 
and analyzed their overall survival based on deﬁnitive local therapy of 
primary disease and the presence or absence of brain metastases. 
Results: 120 patients had brain as a solitary organ site of metastases; of 
them 115 (96%) received local therapy for brain metastases - surgical 
resection, stereotactic radiosurgery, and/or whole brain radiotherapy. 
Of these 120, 10 (8%) also received ablative local therapy of primary 
disease - 8 (6%) with radiotherapy ≥ 45 Gy or 2 (2%)with surgical 
resection of primary tumor and locoregional lymph nodes. Another 
221 patients had a solitary organ site of metastasis outside the brain; of 
them 61 (28%) received local palliative radiotherapy for metastases. 
Of these 221, 35 (16%) also received ablative local therapy of primary 
disease - 33 (15%) with radiotherapy ≥ 45 Gy or 2 (1%) with surgical 
resection of primary tumor and locoregional lymph nodes. In those 
with brain as a solitary organ site of metastasis and single metasta-
sis, there was a marked improvement in survival with resection or 
radiotherapy ≥ 45 Gy for primary thoracic disease (p=0.00186, median 
survival 30 vs. 7 months). In those with non-CNS solitary organ sites 
of metastases, there is only a tendancy towards improved survival in 
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patients who receive similar local therapy of primary disease (median 
survival 12 vs. 8 months).
Conclusions: For NSCLC patients with brain as a solitary organ site of 
metastasis and a single brain metastasis, radiotherapy or resection for 
primary lung disease markedly improves median survival. For those 
with extracranial solitary organ sites of metastases, local therapy of pri-
mary thoracic disease improves survival, but this beneﬁt is lost in those 
who survive beyond one year. Patients with extracranial metastases 
rarely received local therapy for metastases, whereas brain metastasis 
patients invariably do. Our results suggest a potential beneﬁt and need 
for a prospective study of surgical resection or radiotherapy to all vis-
ible disease in patients with oligometastatic NSCLC. 
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Background: To evaluate the therapeutic efﬁcacy and treatment-
related toxicity of image-guided hypofractionated stereotactic body 
radiotherapy (SBRT) in patients with peripherally or centrally located, 
medically inoperable stage I or isolated recurrent NSCLC. 
Methods: Subjects had pathologically conﬁrmed stage I (n=49) or 
isolated recurrent (n=24) NSCLC. Among 73 patients, 25 patients had 
centrally located lesions deﬁned as within 2 cm of bronchial tree, major 
vessels, esophagus, heart and other mediastinal structures but no direct 
invasion. Internal gross target volume was delineated using maximal 
intensity projection created by combining the data from a 4-D CT da-
taset at different respiratory phases. The clinical target volume was the 
internal gross target volume plus an 8-mm margin, and a 3-mm setup 
uncertainty margin was added to determine the planning target volume. 
For each fraction the patient was aligned using in-room CT-on-rails. 
The prescribed dose was 50 Gy to PTV at daily 12.5 Gy/fraction for 4 
contiguous days. Dose constraint of major mediastinal critical organs 
was 40 Gy less than 10 cc except for esophagus in which 40 Gy was 
limited to less than 1 cc. 
Results: Median follow-up was 18 months (3-28 months). The overall 
progression-free survival rate at the treated site was 95.9%. For stage I 
disease, the complete response (CR), partial response (PR) and stable 
disease (SD) rate were 33%, 35% and 31% respectively. There was no 
signiﬁcant difference in response rate between stage Ia (n=42) and Ib 
(n=7). Two patients (4.1%) developed mediastinal lymph node metasta-
sis. For isolated recurrent disease, the CR, PR and SD rate were 45.8%, 
33.3%, and 12.5% respectively. Mediastinal lymph node metastasis 
happened in three patients (12.5%). There was 6.1% grade II but no 
grade III and above radiation pneumonitis in stage I disease. Three 
patients with recurrent disease had worse dyspnea after SBRT and 
one patients needed nasonal oxygenation. No esophagitis was noted. 
22.8% of patients developed grade II dermatitis at the treated site that 
appears related to the dose (>35 Gy) and volume of the skin treated. 
Three patient developed chronic skin scar and ﬁve patients had chronic 
mild neurogenic chest pain due to intercostal nerve injury. There was 
no increased toxicity noted in centrally located lesions compared with 
peripherally located lesions.
Conclusions: Image-guided SBRT using 50 Gy in four fractions 
achieved excellent local progression-free survival rate with minimal 
toxicity in peripherally or centrally located stage I or isolated recurrent 
NSCLC. Long-term follow up and further studies are needed to evalu-
ate the toxicity of centrally located lesions and higher dose volume 
constraints to critical structures. 
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Background: Radiotherapy is the cornerstone treatment for unresect-
able LA-NSCLC. Outcomes with standard RT scheduling in this patient 
subgroup are poor and new approaches like altered fractionation were 
studied. Even though many trials investigated the value of these new 
strategies, their results were inconsistent. We performed a meta-analy-
sis of those trials to try to clarify this matter.
Methods: We performed a thorough literature search to identify phase 
III randomized trials where standard RT was compared with an altered 
RT fractionation in the treatment of LA-NSCLC. The trials were 
analysed for any relevant end point and a meta-analysis of the selected 
trials was performed.
Results: We found 6 trials with n=1484 (n=793 for HFRT and n=691 
for SRT). An absolute improvement in mortality rate of 4.2% with 
HFRT was shown: 90.7% for SRT vs 86.5% for HFRT (p<0.02), with 
a HR=0.65 (CI 95%: 0.47-0.90). Results persist even excluding RTOG 
8808 and CHART. Two year survival was also improved (31.8 vs 
26.1%). Response rate (data available from 2 studies) were similar: 
60.8 vs. 52.5%; HFRT was associated with a reduction of 28% in local 
failures (HR: 0.72, CI: 0.56-0.93). Toxicity: HFRT produced a signiﬁ-
cantly increased incidence of Grade 3 and 4 esophagitis (18.1 vs. 8.7%, 
p<0.001); but grade 3/4 pneumonitis was less frequent with HFRT (8.2 
vs. 11.6%, p<0.02). 
